Diasorin S.p.a. · MIL:DIA
Diasorin — Q1 2024 Earnings Presentation
18 slides from Diasorin's earnings presentation, May 10, 2024
Slide 1: Q1 2024 Results
XS Oiasorin Q1 2024 RESULTS May 10, 2024 }) Diasorin
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Data in €/mln Q1 2024 @ current @ CER Revenues 289 -0% +0% Immunodiagnostics ex-COVID 186 +8% +9% Molecular Diagnostics ex-COVID 51 +1% +2% Licensed Technologies1 43 +3% +4% COVID 9 -59% -59% Revenues ex-COVID 280 +4% +5% Revenues @ constant perimeter of consolidation1 ex
Slide 6: Q1 2024 Key Facts
Q1 2024 KEY FACTS PRODUCT & BUSINESS DEVELOPMENT IMMUNODIAGNOSTICS • LIAISON® LymeDetect® submitted to the U.S. FDA. MOLECULAR DIAGNOSTICS • Execution of the project to sunset the ARIES molecular diagnostics platform and to consolidate the related customer base on the Diasorin LIAISON® MDX platform.
Slide 7: Managerial Outlook on Q1 2024 Revenues
MANAGERIAL OUTLOOK ON Q1 2024 REVENUES EVOLUTION OF THE BUSINESS IN Q1 2024 (@CER) Total revenues: in line with Q1 2023, despite lower COVID sales and different perimeter of consolidation. Q1 2024 Group revenues (data in €/mln) Ex-COVID revenues at constant perimeter of consolidation1: +7%, of which
Slide 8: Q1 2024 Revenues by Geography
Q1 2024 REVENUES BY GEOGRAPHY Q1 2023 Q1 2024 Rest of the World Rest of the World 16% 15% North America North America Direct Direct 49% 49% Europe Direct Europe Direct 36% 35% 8
Slide 9: Q1 2024 Profitability Profile
Q1 2024 PROFITABILITY PROFILE (data in €/mln @ current exchange rates) 34% 34% 290 289 Adjusted2 EBITDA margin: € 97 million, accounting for 34% of revenues, in line with the result achieved in 2023. 98 97 Q1 2023 Q1 2024 Net Revenues Adjusted2 EBITDA Adjusted2 EBITDA Margin 2 With reference to the
Slide 10: FY 2024 Company Guidance
FY 2024 COMPANY GUIDANCE
Slide 11: FY 2024 Company Guidance
FY 2024 COMPANY GUIDANCE @ CER 2023 Revenues: +5% / +7% excluding Covid; Covid sales equal to ~ 30 €/mln Adjusted2 EBITDA Margin: 32% / 33% 2 With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation 11
Slide 12: Financial Schemes
FINANCIAL SCHEMES
Slide 13: Income Statement
INCOME STATEMENT Q1 change Amounts in million of euros % % 2023 2024 a mount @ c urre nt @ CER Revenues 290 289 -1 -0% +0% ex-COVID Immunodiagnostics 172 186 +14 +8% +9% ex-COVID Molecular Diagnostics 51 51 1 +1% +2% 1 Licensed Technologies 42 43 1 +3% +4% COVID 21 9 -13 -59% -59% Revenues net of Co
Slide 14: Balance Sheet
BALANCE SHEET (Amounts in million of euros) 12/31/2023 03/31/2024 Change Goodwill and intangibles assets 1,925 1,966 +41 Property, plant and equipment 256 261 +5 Other non-current assets 35 34 -0 Net working capital 369 380 +11 Other non-current liabilities (270) (275) -4 Net Invested Capital 2,314
Slide 15: Cash Flow Statement
CASH FLOW STATEMENT Q1 (Amounts in million of euros) 2023 2024 Cash and cash equivalents at the beginning of the period 242 280 Cash provided by operating activities 41 75 Cash provided/(used) in investing activities 22 39 Cash provided/(used) in financing activities 68 (87) Net change in cash and c
Slide 16: Q1 2024 Reconciliation to Consolidated Financial Statements
Q1 2024 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in million of Euro) Gross Margin EBITDA EBIT Net Profit IFRS Financial Statements Measures 191 96 63 46 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 1 1 1 Depre
Slide 17: Q1 2023 Reconciliation to Consolidated Financial Statements
Q1 2023 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in million of Euro) Gross Margin EBITDA EBIT Net Profit IFRS Financial Statements Measures 192 93 60 42 % on Revenues 66% 32% 21% 14% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 5 5 5 Depre
Slide 18: Diasorin
}) Diasorin